Context Therapeutics Inc. (CNTX) stock
CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.18−0.02 (-8.69%)
Close on Nov 13, 2026Market cap $16.61MP/E –Yield –
Context Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Context Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $37.10M, up 64.7% year over year. For fiscal 2025 it was $31.86M, up 40.3% from the year before. The highest annual figure on record is $31.86M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.86M | +40.3% |
| FY2024 | Dec 31, 2024 | $22.70M | +27.7% |
| FY2023 | Dec 31, 2023 | $17.78M | +150.8% |
| FY2022 | Dec 31, 2022 | $7.09M | +86.4% |
| FY2021 | Dec 31, 2021 | $3.81M | +131.8% |
| FY2020 | Dec 31, 2020 | $1.64M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.72M | -34.5% |
| Q2 FY2026 | Jun 30, 2026 | $12.53M | +60.0% |
| Q1 FY2026 | Mar 31, 2026 | $7.02M | +102.6% |
| Q4 FY2025 | Dec 31, 2025 | $11.84M | +370.2% |
| Q3 FY2025 | Sep 30, 2025 | $8.72M | -48.2% |
| Q2 FY2025 | Jun 30, 2025 | $7.83M | +465.6% |
| Q1 FY2025 | Mar 31, 2025 | $3.46M | +75.5% |
| Q4 FY2024 | Dec 31, 2024 | $2.52M | -52.5% |
| Q3 FY2024 | Sep 30, 2024 | $16.83M | +275.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.38M | -60.0% |
| Q1 FY2024 | Mar 31, 2024 | $1.97M | -56.5% |
| Q4 FY2023 | Dec 31, 2023 | $5.30M | +147.2% |
| Q3 FY2023 | Sep 30, 2023 | $4.49M | +115.9% |
| Q2 FY2023 | Jun 30, 2023 | $3.46M | +128.1% |
| Q1 FY2023 | Mar 31, 2023 | $4.53M | +235.5% |
| Q4 FY2022 | Dec 31, 2022 | $2.14M | +65.8% |
| Q3 FY2022 | Sep 30, 2022 | $2.08M | +180.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.52M | +13.8% |
| Q1 FY2022 | Mar 31, 2022 | $1.35M | +208.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.29M | +117.5% |
| Q3 FY2021 | Sep 30, 2021 | $739.60K | +57.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.33M | – |
| Q1 FY2021 | Mar 31, 2021 | $438.74K | – |
| Q4 FY2020 | Dec 31, 2020 | $594.84K | – |
| Q3 FY2020 | Sep 30, 2020 | $468.67K | – |
See a number that looks wrong?